Company profile
Poseida Therapeutics, Inc.
Privately held: no public share price (Cell/gene therapy company (Nasdaq: PSTX) acquired by Roche via tender offer that closed 2025-01-08 (Roche press release, prnewswire); shares ceased trading on Nasdaq Global Select Market following the merger. GLEIF LEI XTIQ status is now LAPSED, consistent with the entity no longer being an independent public filer. Kept as its own company row (Roche attribution is a rights/acquirer question, not identity) rather than merged into Roche's own roster row. Sources: https://clinicaltrials.gov/study/NCT03288493 Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BCMACell therapy | Multiple Myeloma | |
| Phase 1 | MUC1-CCell therapy | Non-Small Cell Lung Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.